LEXICON PHARMACEUTICALS, INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
LEXICON PHARMACEUTICALS, INC. (LXRX) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $1.77 million as of 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Notes › Intangible Assets › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2020-03-12
- 2019-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.77M.
- 2018-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.77M.
- 2017-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.77M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2019-12-31 | $1.77M 10-K · filed 2020-03-12 |
| 2018-12-31 | $1.77M 10-K · filed 2019-03-15 |
| 2017-12-31 | $1.77M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |